Related Experiment Video
Updated: Apr 20, 2026
Assessment of Sexual Behavior of Male Mice
Published on: March 5, 2020
Effects of methylphenidate on the behavior of male 5xFAD mice
F Schneider1, K Baldauf1, W Wetzel2
1German Centre for Neurodegenerative Diseases (DZNE), Magdeburg D-39120, Germany.
Abstract:
Alzheimer's disease is a neurodegenerative disorder characterized by a loss of memory and spatial orientation. It is also reported that the dopamine system is affected. Dopamine plays a prominent role in motor functions, motivation, emotion, arousal and reward, and it is important for learning and memory. One model that represents characteristic hallmarks of Alzheimer's disease is the 5xFAD mouse model, in which parenchymal plaque load starts at 2months of age. Transgenic 5xFAD mice show the first behavioral deficits at 6months, which are evident at 9months of age. In this study, we investigated the pharmacological influence of methylphenidate (MPH) on behavioral deficits of 5xFAD mice. Using a battery of behavioral tests, we observed no influence of MPH on anxiety in the elevated plus maze, whereas the locomotion and explorative activity in the open field was increased in transgenic and non-transgenic 5xFAD mice after the application of MPH. Further MPH inhibits habituation in the open field in healthy 5xFAD littermates after the application of 10mg/kg MPH. On the other hand, 10mg/kg MPH improved spatial memory in 6-month-old transgenic 5xFAD males, i.e., at a time point when deficits start to occur. However, in 9-month-old transgenic mice, MPH did not improve persisting learning and memory deficits. We concluded that MPH might improve the non-cognitive, apathy-like behavior (indicated by a reduced exploration), but it has no influence on sustained Alzheimer typical learning and memory deficits.
Insights
Methylphenidate (MPH) did not improve learning and memory deficits in the 5xFAD mouse model of Alzheimer's disease. However, MPH did show potential in improving apathy-like behaviors and spatial memory in early stages.
Area of Science:
- Neuroscience
- Pharmacology
- Alzheimer's Disease Research
Background:
- Alzheimer's disease (AD) is a neurodegenerative disorder impacting memory and spatial orientation, with dopamine system involvement.
- The 5xFAD mouse model exhibits AD hallmarks, including plaque deposition and behavioral deficits starting at 6 months.
- Dopamine is crucial for motor function, motivation, emotion, reward, learning, and memory.
Purpose of the Study:
- To investigate the pharmacological effects of methylphenidate (MPH) on behavioral deficits in the 5xFAD mouse model of Alzheimer's disease.
- To assess MPH's influence on anxiety, locomotion, explorative activity, and spatial memory in 5xFAD mice at different disease stages.
Main Methods:
- Utilized the 5xFAD transgenic mouse model exhibiting Alzheimer's-like pathology.
- Administered methylphenidate (MPH) at a dose of 10mg/kg.
- Conducted a battery of behavioral tests, including the elevated plus maze and open field test, to assess anxiety, locomotion, exploration, and spatial memory.
Main Results:
- Methylphenidate (MPH) did not affect anxiety levels in the elevated plus maze.
- MPH increased locomotion and explorative activity in both transgenic and non-transgenic 5xFAD mice.
- MPH improved spatial memory in 6-month-old 5xFAD males but failed to improve deficits in 9-month-old mice.
Conclusions:
- Methylphenidate (MPH) may ameliorate non-cognitive, apathy-like behaviors in the 5xFAD mouse model.
- MPH does not significantly improve established learning and memory deficits characteristic of Alzheimer's disease.
- The timing of MPH intervention is critical, showing benefits in early-stage spatial memory deficits but not in later stages.
